Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Prostate cancer polygenic risk score and prediction of lethal prostate cancer
Department of Genetics and Genomic Sciences and Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, NY, New York, United States.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, New York, United States.
Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, NY, New York, United States.
Department of Molecular and Medical Pharmacology, University of California Los Angeles, CA, Los Angeles, United States; Ahmanson Translational Imaging Division, David Geffen UCLA School of Medicine, CA, Los Angeles, United States; Jonsson Comprehensive Cancer Center, David Geffen UCLA School of Medicine, CA, Los Angeles, United States; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California Los Angeles, CA, Los Angeles, United States; Institute of Urologic Oncology, University of California Los Angeles, CA, Los Angeles, United States.
Visa övriga samt affilieringar
2022 (Engelska)Ingår i: npj Precision Oncology, E-ISSN 2397-768X, Vol. 6, nr 1, artikel-id 25Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Polygenic risk scores (PRS) for prostate cancer incidence have been proposed to optimize prostate cancer screening. Prediction of lethal prostate cancer is key to any stratified screening program to avoid excessive overdiagnosis. Herein, PRS for incident prostate cancer was evaluated in two population-based cohorts of unscreened middle-aged men linked to cancer and death registries: the Västerbotten Intervention Project (VIP) and the Malmö Diet and Cancer study (MDC). SNP genotypes were measured by genome-wide SNP genotyping by array followed by imputation or genotyping of selected SNPs using mass spectrometry. The ability of PRS to predict lethal prostate cancer was compared to PSA and a commercialized pre-specified model based on four kallikrein markers. The PRS was associated with incident prostate cancer, replicating previously reported relative risks, and was also associated with prostate cancer death. However, unlike PSA, the PRS did not show stronger association with lethal disease: the hazard ratio for prostate cancer incidence vs. prostate cancer metastasis and death was 1.69 vs. 1.65 in VIP and 1.25 vs. 1.25 in MDC. PSA was a much stronger predictor of prostate cancer metastasis or death with an area-under-the-curve of 0.78 versus 0.63 for the PRS. Importantly, addition of PRS to PSA did not contribute additional risk stratification for lethal prostate cancer. We have shown that a PRS that predicts prostate cancer incidence does not have utility above and beyond that of PSA measured at baseline when applied to the clinically relevant endpoint of prostate cancer death. These findings have implications for public health policies for delivery of prostate cancer screening. Focusing polygenic risk scores on clinically significant endpoints such as prostate cancer metastasis or death would likely improve clinical utility.

Ort, förlag, år, upplaga, sidor
Nature Publishing Group, 2022. Vol. 6, nr 1, artikel-id 25
Nationell ämneskategori
Cancer och onkologi
Identifikatorer
URN: urn:nbn:se:umu:diva-194353DOI: 10.1038/s41698-022-00266-8ISI: 000781349700001PubMedID: 35396534Scopus ID: 2-s2.0-85128179283OAI: oai:DiVA.org:umu-194353DiVA, id: diva2:1655659
Forskningsfinansiär
Cancerfonden, 2017/559Vetenskapsrådet, 2016-02974Tillgänglig från: 2022-05-03 Skapad: 2022-05-03 Senast uppdaterad: 2023-05-24Bibliografiskt granskad

Open Access i DiVA

fulltext(1248 kB)84 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1248 kBChecksumma SHA-512
6a94a59454a5ea55ff1d2a7c3be263d3ddec346493a240a7608ee036d8db09bbdfc64c9407cfb55098ededcb89e3b9947ffee6b7233a3adf34afe14d59f09173
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Häggström, ChristelThysell, ElinHallmans, Göran

Sök vidare i DiVA

Av författaren/redaktören
Häggström, ChristelThysell, ElinHallmans, Göran
Av organisationen
Enheten för biobanksforskningPatologiAvdelningen för hållbar hälsa
I samma tidskrift
npj Precision Oncology
Cancer och onkologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 84 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 213 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf